TT5 Stock Overview
Xtacy Therapeutics Corp. formerly known as Global Wellness Strategies Inc.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Xtacy Therapeutics Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.008 |
| 52 Week High | CA$0.046 |
| 52 Week Low | CA$0.0035 |
| Beta | -0.72 |
| 11 Month Change | -42.86% |
| 3 Month Change | -55.56% |
| 1 Year Change | -80.10% |
| 33 Year Change | -94.67% |
| 5 Year Change | -94.29% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| TT5 | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | 4.5% |
| 1Y | -80.1% | 29.0% | 13.4% |
Return vs Industry: TT5 underperformed the German Capital Markets industry which returned 29% over the past year.
Return vs Market: TT5 underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| TT5 volatility | |
|---|---|
| TT5 Average Weekly Movement | 61.9% |
| Capital Markets Industry Average Movement | 4.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TT5's share price has been volatile over the past 3 months.
Volatility Over Time: TT5's weekly volatility has decreased from 85% to 62% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Meris Kott | xtacytherapeutics.com |
Xtacy Therapeutics Corp. formerly known as Global Wellness Strategies Inc. is an incubator, venture capital and accelerator firm specializing in incubation and startup. The firm seeks to invest in the public and private sectors that focus on preventative health, wellness issues, related consumer products, biotechnology, specific areas of pain, Psychedelic, depression, mental illness health and medicine sectors. By investing in pioneering techniques such as micro-dosing using organic compounds and synthetic molecules, we are focussing on ground breaking research with the aim of providing superior wellness benefits with less side effects, better for peoples and the planet.
Xtacy Therapeutics Corp. Fundamentals Summary
| TT5 fundamental statistics | |
|---|---|
| Market cap | €963.33k |
| Earnings (TTM) | -€129.65k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs TT5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TT5 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$195.68k |
| Earnings | -CA$195.68k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0034 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -5.1% |
How did TT5 perform over the long term?
See historical performance and comparison